The Neuroscience Institute

The Neuroscience Institute is well-known as a leader in the diagnosis and treatment of brain and spine disorders. Yet, more and more it is being recognized for its cutting-edge research toward advancing the treatment of these often disabling, or even fatal, disorders. The Neuroscience Research group investigates the cellular, molecular and biochemical associations with brain injuries and disorders to better understand the processes and mechanisms of the disorderly functions associated with disease or injury. Their overarching goal is to identify novel opportunities for therapeutic intervention on behalf of patients

Currently, the Neuroscience Research group focuses on two significant areas: traumatic brain injury (TBI) and stroke.

Traumatic brain injury is a physical brain injury that temporarily or permanently impairs cognitive function, and they are on the rise. TBI is significant cause of death and disability worldwide, particularly among the young population, yet also a major concern for the elderly, largely due to falls.

Led by Mohammed Muneer, PhD, this research group looks to develop standard-of-care practices by integrating various therapeutic approaches which will have great significance for patients, especially given the noticeable increase in TBI incidents. Currently their research includes a range of novel strategies to improve recovery after central nervous system injuries by mitigating oxidative signaling. By developing clinical trials in collaboration with other clinical faculties and with physicians of the JFK Neuroscience Institute, the Research group anticipates finding better ways to safely detect, treat, and ultimately prevent TBI. By participating in a clinical study, healthy individuals and those with TBI can greatly benefit the lives of those living with this disorder.

Stroke is a leading cause of disability and death in the United States. Every year, about 800,000 Americans have a stroke and 130,000 people succumb to injuries related to strokes. Nearly 90 percent of these are ischemic strokes, which is the focus of the research group led by Ashutosh Dharap, PhD. Despite these staggering numbers and numerous clinical trials over the years, there is currently no FDA-approved therapeutic intervention that can ameliorate brain damage following a stroke.

This group’s research focuses on developing a clearer understanding of the molecular and cellular events that drive post-stroke brain damage and investigate how blocking harmful pathways might improve neuroprotection. They are investigating various strategies to upset destructive mechanisms to reduce overall cell death and improve neurological function after stroke. They will take advantage of the clinical expertise at the Neuroscience Institute to advance this work to clinical trials in order to translate laboratory findings to clinical settings in direct service of stroke patients. In the long-term, this work will help us reduce post-stroke brain damage and help conserve brain function in stroke patients. This will directly contribute to improved prognosis and quality of life for stroke survivors.